Global Allergy Immunotherapies Market 2019-2023 | Increasing Prevalence of Allergies Impacting the Market Growth | Technavio
LONDON--(BUSINESS WIRE)--Nov 19, 2018--The global allergy immunotherapies market 2019-2023 is expected to post a CAGR of more than 7% during the forecast period, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005356/en/
Technavio predicts the global allergy immunotherapies market to post a CAGR of more than 7% by 2023. (Graphic: Business Wire)
A key factor driving the growth of the market is an increasing prevalence of allergies. Globally, the prevalence of various types of allergies is very strong and it is one of the most common and fastest ailments, with approximately over 500 million people having it. The huge unmet need for allergy treatment has led to various vendors conducting research on novel therapies, thus resulting in advances in the field of immunology therapeutics for allergies. Hence, the global allergy immunotherapies market is expected to witness significant growth during the forecast period.
This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
In this report, Technavio highlights the technological advances in allergy diagnostics as one of the key emerging trends in the global allergy immunotherapies market:
Global allergy immunotherapies market: Technological advances in allergy diagnostics
One of the significant challenges faced by the global allergy immunotherapies market is the unclear pathogenesis and prognosis of various allergy indications. The unclear pathogenesis of these allergies leads to poor diagnosis. Thus, the lack of effective diagnostic methods led various companies to conduct research on developing novel therapies to diagnose various allergies. Also, the recent advances are helping in increasing the number of patients being diagnosed in the early stages of allergy and hence, making treatment more effective.
“Siemens Healthcare manufactured IMMULITE 2000 XPi immunoassay system, which is being used for the diagnosis of various medical conditions such as allergy, anemia, reproductive endocrinology and thyroid. These advances are expected to lead to the identification of new allergens, which will lead to the development of better immunotherapies, thus resulting in the growth of the market in the coming years,” says a senior analyst at Technavio for research on pharmaceuticals.
Global allergy immunotherapies market: Segmentation analysis
This market research report segments the global allergy immunotherapies market by product (SCIT and SLIT) and geographical regions (APAC, EMEA, and the Americas).
EMEA led the market in 2018 with a market share of more than 65%, followed by the Americas and APAC respectively. EMEA has seen significant growth in demand for allergy immunotherapies, largely due to the high prevalence of allergies in developed countries of Europe.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20181119005356/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 11/19/2018 11:16 AM/DISC: 11/19/2018 11:16 AM